Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Irvine
• Collaborator: Merck Sharp & Dohme LLC
• Treatments: Glycopyrrolate; Neostigmine

Criteria

Inclusion Criteria:

• Age 18 or older

• Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission

Exclusion Criteria:

• Allergy to Rocuronium, Vecuronium, or Sugammadex

• Bowel resection surgery requiring an ostomy

• No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality

• No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin

• Creatinine Clearance (CrCl) of less than 30

• Pregnancy

• Incapable of providing consent or understanding the research project